Serotonergic drugs: Effects on appetite expression and use for the treatment of obesity

Drugs

Volumn 67, Issue 1, 2007, Pages 27-56

  Halford, Jason C G ^a,b   Harrold, Joanne A ^a   Boyland, Emma J ^a   Lawton, Clare L ^b   Blundell, John E ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDIN 5 ONE; 5 METHOXY 3 (1,2,3,6 TETRAHYDRO 4 PYRIDYL) 1H INDOLE; 5 PROPOXY 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDINE; 6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ADP 356; AMPHETAMINE; BVT 74316; DEXFENFLURAMINE; FENFLURAMINE; FLUOXETINE; LORCASERIN; MELANOCORTIN; METERGOLINE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NEUROPEPTIDE Y; OREXIN; PAROXETINE; PLACEBO; PRX 07034; SEROTONIN; SEROTONIN 1 ANTAGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN 6 ANTAGONIST; SEROTONIN AGONIST; SERTRALINE; SIBUTRAMINE; UNCLASSIFIED DRUG;

ANOREXIA; APPETITE; BODY WEIGHT; CACHEXIA; CALORIC INTAKE; CANCER MODEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG STRUCTURE; FEEDING BEHAVIOR; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; HUNGER; HYPOPHAGIA; NONHUMAN; NUTRITIONAL STATUS; OBESITY; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SATIETY; SIGNAL TRANSDUCTION; WEIGHT CONTROL; WEIGHT GAIN; WEIGHT REDUCTION;

RODENTIA;

EID: 33846246036     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767010-00004     Document Type: Review

References (150)

1. Halford JCG, Blundell JE. Separate systems for serotonin and leptin in appetite control. Ann Med 2000; 32: 222-32
2. Vickers SP, Dourish CT. Serotonin receptor ligands and the treatment of obesity. Curr Opin Invest Drugs 2004; 5: 377-88
3. Bentley JM, Adams DR, Bebbington D. Indoline derivatives as 5-HT2C receptor agonists. Bioorg Med Chem Let 2004; 14: 2367-70
4. Bray GA, York DA. Studies on food intake of genetically obese rats. Am J Physiol 1972; 233: 176-9
5. Jesperson S, Scheel-Kruger J. Evidence for a difference in mechanism of action between fenfluramine- and amphetamine-induced anorexia. J Pharm Pharmacol 1973; 22: 637-8
6. Barrett AM, McSherry L. Inhibition of drug-induced anorexia in rats by methysergide. J Pharm Pharmacol 1975; 27: 889-95
7. Pinder BM, Brogden RN, Sawyer PR, et al. Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. Drugs 1975; 10: 241-323
8. Garattini S, Samanin R. Anorectic drugs and brain neurotransmitters. In: Silverstone T, editor. Food intake and appetite. Berlin: Dahlem Konferenzen, 1976: 82-208
9. MacKenzie RG, Hoebel BG, Ducret RP, et al. Hyperphagia following intraventricular p-chlorophenylalanine-, leucine- or tryptophan-methyl esters: lack of correlation with whole brain serotonin levels. Pharmacol Biochem Behav 1979; 10: 951-5
10. Blundell JE. Is there a role for serotonin (5-hydroxytryptamine) in feeding? Int J Obesity 1977; 1: 15-42
11. Hoyer D, Martin G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 1997; 36: 419-28
12. Blundell JE, Halford JCG. Serotonin and appetite regulation: implications for the treatment of obesity. CNS Drugs 1998; 9: 473-95
13. Rogers P, McKibbin PE, Williams G. Acute fenfluramine administration reduces neuropeptide Y concentrations in specific hypothalamic regions of the rat: possible implications for the anorectic effect of fenfluramine. Peptides 1991; 12: 251-5
14. Brown CM, Coscina DV. Ineffectiveness of hypothalamic serotonin to block neuropeptide Y-induced feeding. Pharmacol Biochem Behav 1995; 51: 641-6
15. Compan V, Dusticier N, Nieoullon A, et al. Opposite changes in striatal neuropeptide Y immunoreactivity after partial and complete serotonergic depletion in the rat. Synapse 1996; 24: 87-96
16. Currie PJ. Integration of hypothalamic feeding and metabolic signals: focus on neuropeptide Y. Appetite 2003; 41: 335-7
17. Heisler LK, Cowley MA, Tecott LH, et al. Activation of central melanocortin pathways by fenfluramine. Science 2002; 297: 609-11
18. Heisler LK, Cowley MA, Kishi T, et al. Central serotonin and melanocortin pathways regulating energy homeostasis. N Y Acad Sci 2003; 994: 169-74
19. Heisler LK, Jobst EE, Sutton GM, et al. Serotonin reciprocally regulated melanocortin neurons to modulate food intake. Neuron 2006; 51: 239-49
20. Nambu T, Sakurai T, Mizukami K, et al. Distribution of orexin neurons in the adult rat brain. Brain Res 1999; 827: 243-60
21. Hervieu GJ, Cluderay JE, Harrison DC, et al. Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. Neuroscience 2001; 103: 777-97
22. Marcus JN, Aschkenasim CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001; 435: 6-25
23. Brown RE, Sergeeva OA, Eriksson KS, et al. Convergent excitation of dorsal raphe serotonin neurons by multiple arousal systems (orexin/hypocretin, histamine and noradrenaline). J Neurosci 2002; 22: 8850-9
24. Cai XJ, Liu XH, Evans M, et al. Orexins and feeding: special occasions or everyday occurrence? Reg Peptides 2002; 104: 1-9
25. Orlando G, Brunetti Ll, Di Nisio C, et al. Effects of cocaine- and amphetamine-regulated transcript peptide, leptin and orexins on hypothalamic serotonin release. Eur J Pharmacol 2001; 430: 269-72
26. Matsuzaki I, Sakurai T, Kunii K, et al. Involvement of the serotonergic system in orexin-induced behavioral alterations in rats. Reg Peptides 2002; 104: 119-23
27. Brown RE, Sergeeva O, Eriksson KS, et al. Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat. Neuropharmacology 2001; 40: 457-9
28. Simansky KJ. Serotoninergic control of the organisation of feeding and satiety. Behav Brain Res 1996; 73: 37-42
29. Hewitt KN, Lee MD, Dourish CT, et al. Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacol Biochem Behav 2002; 71: 691-700
30. Collin M, Backberg M, Onnestam K, et al. 5-HT1A receptor immunoreactivity in hypothalamic neurons involved in body weight control. Neuroreport 2002; 13: 945-51
31. Muraki Y, Yamanaka A, Tsujino N, et al. Serotonergic regulation of the orexin/hypocretin neurons through the 5-HT1A receptor. J Neurosci 2004; 24: 7159-66
32. Barrafan-Majia MG, Castilla-Serna L, Calderon-Guzman D, et al. Effect of nutritional status and ozone exposure on rat brain serotonin. Arch Med Res 2002; 33: 15-9
33. Xie QW. Experimental studies on changes of neuroendocrine functions during starvation and refeeding. Neuroendocrinology 1991; 53: 52-9
34. Nishimura F, Nishihara M, Torii K, et al. Changes in responsiveness to serotonin on rat ventromedial hypothalamic neurons after food deprivation. Physiol Behav 1996; 60: 7-12
35. Wolfe BW, Metzger ED, Stollar C. The effects of dieting on plasma tryptophan concentration and food intake in healthy women. Physiol Behav 1997; 61: 537-41
36. Cowen PJ, Clifford EM, Walsh AES, et al. Moderate dieting causes 5-HT2C supersensitization. Psychol Med 1996; 26: 1156-9
37. Varma M, Torelli GF, Meguid MM, et al. Potential strategies for ameliorating early cancer anorexia. J Surg Res 1998; 81: 69-76
38. Yang ZJ, Blaha V, Meguid MM, et al. Interleukin-1α injection into ventromedial hypothalamic nucleus of normal rats depresses food intake and increases release of dopamine and serotonin. Pharmacol Biochem Behav 1999; 62: 61-5
39. Cangiano C, Laviano A, Muscaritoli M, et al. Cancer anorexia: new pathogenic and therapeutic insights. Nutrition 1996; 12: S48-51
40. Cangiano C, Testa U, Muscaritoli M, et al. Cytokines, tryptophan and anorexia in cancer patients before and after surgical tumor ablation. Anticancer Res 1994; 14: 1451-5
41. Meguid MM, Fetissov SO, Blaha V, et al. Dopamine and serotonin VMN release is related to feeding status in obese and lean Zucker rats. Neuroreport 2000; 11: 2069-72
42. Svec F, Thompson H, Porter J. Levels of hypothalamic neurotransmitters in lean and obese Zucker rats. Nutr Neurosci 2002; 5: 321-6
43. Harrold JA, Widdowson PS, Clapham JC, et al. Individual severity of dietary obesity in unselected Wistar rats: relationship with hyperphagia. Am J Physiol 2000; 279: E340-7
44. Hassanain M, Levin BE. Dysregulation of hypothalamic serotonin turnover in diet-induced obese rats. Brain Res 2002; 929: 175-80
45. Breum L, Rasmussen MH, Hilsted J. Twenty-four-hour plasma tryptophan concentrations and ratios are below normal in obese subjects and are not normalized by substantial weight reduction. Am J Clin Nutr 2003; 77: 1112-8
46. Clifton PG. The neuropharmacology of meal patterning. In: Cooper SJ, editor. Ethology and psychopharmacology. Chichester: Wiley, 1994: 313-28
47. Neill JC, Cooper SJ. Evidence that d-fenfluramine anorexia is mediated by 5-HT1 receptors. Psychopharmacology 1989; 97: 213-8
48. Samanin R, Mennini T, Bendotti C, et al. Evidence that central 5-HT2C receptors do not play an important role in anorectic activity of d-fenfluramine in the rat. Neuropharmacology 1989; 28: 465-9
49. Neill JC, Bendotti C, Samanin R. Studies on the role of 5-HT receptors in satiation and the effect of d-fenfluramine in the runway test. Eur J Pharmacol 1990; 190: 105-12
50. Simansky JJ, Nicklous DM. Parabrachial infusion of -fenfluramine reduces food intake: blockade by the 5-HT1B antagonist SB-216641. Pharmacol Biochem Behav 2002; 71: 681-90
51. Vickers SP, Dourish CT, Kennett GA. Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology 2001; 41: 200-9
52. Wong DT, Reid LR, Threlkeld PG. Suppression of food intake in rats by fluoxetine: comparison of enantiomers and effects of serotonin antagonists. Pharmacol Biochem Behav 1988; 31: 475-9
53. Grignaschi G, Samanin R. Role of serotonin and catecholamines in brain in feeding suppressant effects of fluoxetine. Neuropharmacology 1992; 31: 445-9
54. Lightowler S, Wood M, Brown T, et al. An investigation of the mechanism responsible for fluoxetine-induced hypophagia in rats. Eur J Pharmacol 1996; 296: 137-43
55. Lee MD, Clifton PG. Partial reversal of fluoxetine anorexia by the 5-HT antagonist metergoline. Psychopharmacology 1992; 107: 359-64
56. Halford JCG, Blundell JE. Metergoline antagonizes fluoxetine induced suppression of food intake but not changes in the behavioural satiety sequence. Pharmacol Biochem Behav 1996; 54: 745-51
57. Koe BK, Weissman A, Welch WM, et al. Sertraline, 1S,4S-N-methyl-4(3,4- dichlorophenyl)-1,2,3,4-tetrahydro-1-naphathylamine, a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther 1983; 266: 686-700
58. Lucki I, Kreider MS, Simansky KJ. Reduction of feeding behaviour by the serotonin uptake inhibitor sertraline. Psychopharmacology 1988; 96: 289-95
59. Kennett GA, Curzon G. Evidence that the hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU-24969 only requires 5-HT1B receptors. Psychopharmacology 1988; 96: 93-100
60. Kennett GA, Curzon G. Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors. Br J Pharmacol 1988; 94: 137-47
61. Kennett GA, Curzon G. Potencies of antagonists indicate that 5-HT1C receptors mediate 1-3(chlorophenyl)piperazine-induced hypophagia. Br J Pharmacol 1991; 10: 2016-20
62. Halford JCG, Blundell JE. The 5-HT1B receptor agonist CP-94,253 reduces food intake and preserves the behavioural satiety sequence. Physiol Behav 1996; 60: 933-9
63. Lee MD, Simansky KJ. CP-94,253: a selective serotonin1B (5-HT1B) agonist that promotes satiety. Psychopharmacology 1997; 131: 264-70
64. Schreiber R, Selbach K, Asmussen M, et al. Effects of serotonin1/2 receptor agonists on dark-phase food and water intake in rats. Pharmacol Biochem Behav 2000; 67: 291-305
65. Clifton PG, Lee MD, Dourish CT. Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist, and d-fenfluramine on feeding patterns in the rat. Psychopharmacology 2000; 152: 256-67
66. Lee MD, Kennett GA, Dourish CT, et al. 5-HT1B receptors modulate components of satiety in the rat: behavioural and pharmacological analyses of the selective serotonin1B agonist CP-94,253. Psychopharmacology 2002; 164: 49-60
67. Blundell JE, Latham CJ. Pharmacological manipulation of feeding behaviour: possible influences of serotonin and dopamine on food intake. In: Garattini S, Samanin R, editors. Central mechanisms of anorectic drugs. New York (NY): Raven Press, 1978: 83-109
68. Halford JCG, Wanninayake SCD, Blundell JE. Behavioural satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 1998; 61: 159-68
69. Blundell JE, Latham CJ. Characteristic adjustments to the structure of feeding behaviour following pharmacological treatments: effects of amphetamine and fenfluramine and the antagonism by pimozide and metergoline. Pharmacol Biochem Behav 1980; 12: 717-22
70. Blundell JE, McArthur RA. Behavioural flux and feeding: continuous monitoring of food intake and food selection, and the video-recording of appetitive and satiety sequences for the analysis of drug action. In: Samanin R, Garattini S, editors. Anorectic agents: mechanisms of action and tolerance. New York (NY): Raven Press, 1981: 19-43
71. Halford JCG, Blundell JE. 5-Hydroxytryptaminergic drugs compared on the behavioural sequence associated with satiety. Br J Pharmacol 1993; 100: 95
72. Clifton PG, Barnfield AMC, Philcox L. A behavioural profile of fluoxetine induced anorexia. Psychopharmacology 1989; 97: 89-95
73. Simansky KJ, Viadya AH. Behavioural mechanisms for the anorectic actions of the serotonin (5-HT) uptake inhibitor sertraline in rats: comparison with directly acting agonists. Brain Res Bull 1990; 25: 953-60
74. McGuirk J, Muscat R, Willner P. Effects of the 5-HT uptake inhibitors femoxetine and parpexetine, and the 5-HT1A agonist cltoprazine, on the behavioural satiety sequence. Pharmacol Biochem Behav 1992; 41: 801-5
75. Kitchener SJ, Dourish CT. An examination of the behavioural specificity of hypophagia induced by 5-HT1B, 5-HT1C and 5-HT2 receptor agonists using the post-prandial sequence in rats. Psychopharmacology 1994; 113: 368-77
76. Tecott LH, Sun LM, Akanna SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 1995; 374: 542-6
77. Nonogaki K, Abdullah L, Goulding EH, et al. Hyperactivity and reduced energy cost of physical activity in serotonin 5-HT2C receptor mutant mice. Diabetes 2003; 52: 315-20
78. Vickers SP, Clifton PG, Dourish CT, et al. Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice. Psychopharmacology 1999; 143: 309-14
79. Bouwknecht JA, van der Guten J, Hijsenm TH, et al. Male and female 5-HT1B receptor knockout mice have higher body weights than wildtypes. Physiol Behav 2001; 74: 507-16
80. Silverstone T, Goodall E. The clinical pharmacology of appetite suppressant drugs. Int J Obes 1984; 8 (1): 23-33
81. Cangiano C, Ceci F, Casinco A, et al. Eating behaviour and adherence to dietary prescription in obese adult subjects treated with 5-hydroxytryptophan. Am J Clin Nutr 1992; 56: 863-7
82. Rogers PJ, Blundell JE. Effect of anorexic drugs on food intake and the micro-structure of eating in human subjects. Psychopharmacology 1979; 66: 159-65
83. Hill AJ, Blundell JE. Sensitivity of the appetite control system in obese subjects to nutritional and serotoninergic challenges. Int J Obesity 1990; 14: 219-33
84. Wurtman JJ, Wurtman RJ, Growdon JH, et al. Carbohydrate craving in obese people: suppression by treatments affecting serotonergic transmission. Int J Eat Disord 1982; 1: 2-15
85. Wurtman JJ, Wurtman RJ, Mark S, et al. d-Fenfluramine selectively suppresses carbohydrate snacking in obese subjects. Int J Eat Disord 1985; 4: 89-99
86. Goodall E, Silverstone T. Differential effect of d-fenfluramine and metergoline on food intake in human subjects. Appetite 1988; 11: 215-88
87. Blundell JE, Hill AJ. On the mechanism of action of dexfenfluramine: effect on alliesthesia and appetite motivation in lean and obese subjects. Clin Neuropharmacol 1988; 11 Suppl. 1: 121-34S
88. Goodall EM, Cowen PJ, Franklin M, et al. Ritanserin attenuates anorectic endocrine and thermic responses to d-fenfluramine in human volunteers. Psychopharmacology 1993; 112: 461-6
89. McGuirk J, Silverstone T. The effect of 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. Int J Obesity 1990; 14: 361-72
90. Lawton CL, Wales JK, Hill AJ, et al. Serotoninergic manipulation, meal-induced satiety and eating patterns: effects of fluoxetine in obese female subjects. Obes Res 1995; 3: 345-56
91. Wadden TA, Bartlet SJ, Foster GD, et al. Sertraline and relapse prevention following treatment by a very low calorie diet: a controlled clinical trial. Obes Res 1995; 3: 549-57
92. Walsh AE, Smith KA, Oldman AD. m-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology 1994; 116: 120-2
93. Sargent PA, Sharpley AL, Williams C, et al. 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology 1997; 133: 309-12
94. Boeles S, Williams C, Campling GM, et al. Sumatriptan decreases food intake and increases plasma growth hormone in healthy women. Psychopharmacology 1997; 129 (Pt 2): 179-82
95. Rolls BJ, Shide DJ, Thorward ML, et al. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998; 6: 1-11
96. Cangiano C, Laviano A, Del Ben M, et al. Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients. Int J Obesity 1988; 22: 648-54
97. Foltin RW, Haney M, Comer S, et al. Effect of fenfluramine on food intake, mood, and performance of humans living in a residential laboratory. Physiol Behav 1996a; 59: 295-305
98. Drent ML, Zelissen PMJ, Kopperchaar HPF, et al. The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks. Int J Obesity 1995; 19: 299-304
99. Pijl H, Koppeschaar HPF, Willekens FLA, et al. Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. Int J Obesity 1991; 15: 237-42
100. Ward AS, Comer SD, Haney M, et al. Fluoxetine-maintained obese humans: effect on food intake and body weight. Physiol Behav 1999; 66: 815-21
101. Chapelot D, Mamonier C, Thomas F, et al. Modalities of the food intake-reducing effect of sibutramine in humans. Physiol Behav 2000; 68: 299-308
102. Hansen DL, Toubro S, Stock MJ, et al. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998; 68: 1180-6
103. Hansen DL, Toubro S, Stock MJ, et al. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obesity 1999; 23: 1016-24
104. Barkeling B, Elfhag K, Rooth P, et al. Short-term effects of sibutramine (Reductil.) on appetite and eating behaviour and the long-term therapeutic outcome. Int J Obesity 2003; 27: 693-700
105. Cowen PJ, Sargent PA, Williams C, et al. Hypophagic, endocrine and subjective responses to m-chlorophenylpiperazine in healthy men and women. Hum Psychopharmacol 1995; 10: 385-91
106. Ghaziuddin N, Welch K, Greden J. Central serotonergic effects of m-chlorophenylpiperazine (mCPP) among normal control adolescents. Neuropsychopharmacology 2003; 28: 133-9
107. Fisler JS, Undernerger SJ, York DA, et al. d-Fenfluramine in a rat model of dietary fat-induced obesity. Pharmacol Biochem Behav 1993; 45: 487-93
108. Vickers SP, Benwell KR, Porter RH, et al. Comparative effects of continuous infusion of mCPP, Ro 60-0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats. Br J Pharmacol 2000; 130: 1305-14
109. Vickers SP, Easton N, Webster LJ, et al. Oral administration of the 5-HT2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology 2003; 167: 274-80
110. Yen TT, Wong DT, Bemis KG. Reduction of food consumption and body weight of normal and obese mice by chronic treatment with fluoxetine: a serotonin reuptake inhibitor. Drug Dev Res 1987; 10: 37-45
111. Fuller RW, Wong DT. Fluoxetine: a serotonergic appetite suppressant drug. Drug Dev Res 1989; 17: 1-15
112. Nielsen JA, Chapin DS, Johson JL, et al. Sertraline, a serotonin-uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice. Am J Clin Nutr 1992; 55: 185-8s
113. Wieczorek I, Schulz C, Jarry H, et al. The effects of the selective serotonin reuptake-inhibitor fluvoxamine on body weight in Zucker rats are mediated by corticotropin-releasing hormone. Int J Obesity 2001; 25: 1566-9
114. Konkle ATM, Sreter KB, Bajer SL, et al. Chronic paroxetine infusion influences macronutrient selection in male Sprague-Dawley rats. Pharmacol Biochem Behav 2003; 74: 883-90
115. Kennett GA, Wood MD, Bright F, et al. SB 242084, a selective and brain potent 5-HT2C receptor. Neuropharmacology 1997; 36: 609-20
116. Hayashi A, Sonoda R, Kimura Y, et al. Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats. Brain Res 2004; 1011: 221-7
117. Bjenning C, Williams J, Whelan K, et al. Chronic oral administration of APD356 significantly reduces body weight and fat mass in obesity-prone (DIO) male and female rats. Int J Obesity 2004; 28 (1 Suppl.): 214s
118. Haddock CK, Poston WSC, Dill PL, et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obesity 2002; 26: 262-73
119. Pinder RM, Brogden RN, Sawyer PR, et al. Fenfluramine: a review of the pharmacological properties and therapeutic efficacy in obesity. Drugs 1975; 10: 241-323
120. Guy-Grand B, Apfelbaum M, Creoaldi C, et al. International trial of long-term dexfenfluramine in obesity. Lancet 1989; Nov 11: 1142-5
121. Guy-Grand B. Clinical studies with d-fenfluramine. Am J Clin Nutr 1992; 55: 173-6s
122. Finer N, Finer S, Naoumova RP. Drug therapy after very-low-calorie-diets. Am J Clin Nutr 1992; 56: 195-8s
123. James WPT, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000; 356: 2119-25
124. McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160: 2185-91
125. Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001; 50: 505-12
126. McNulty SJ, Ur E, Williams G. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003; 26: 125-33
127. Poston WSC, Reeves RS, Haddock CK, et al. Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification. Int J Obesity 2003; 27: 1486-93
128. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004; 164: 994-1003
129. Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obesity 2003; 27: 1437-46
130. Wise SD. Clinical studies with fluoxetine in obesity. Am J Clin Nutr 1992; 55: 181-4s
131. Goldstein DJ, Rampey AH, Roback PJ, et al. Efficacy and safety of long-term fluoxetine treatment of obesity -maximising success. Obes Res 1995; 3 Suppl. 4: 481-90s
132. Darga LL, Carroll-Michals C, Botsford SJ, et al. Fluoxetine's effect on weight loss in obese subjects. Am J Clin Nutr 1991; 54: 315-21
133. Goldstein DJ, Rampey AH, Enas GG, et al. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obesity 1994; 18: 129-35
134. Simpson RJ, Lawton DJ, Watt MH, et al. Effect of zimelidine, a new antidepressant, on appetite and body weight. Br J Clin Pharmacol 1981; 11: 96-8
135. Van Baak M, Lentjes M, Mujakovic S, et al. Behavior modification and societal change in the prevention of obesity. Obes Res 2003; 11 (1 Suppl.): A111
136. Halford JCG. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr Drug Targets 2004; 5: 637-46
137. Abeniam L, Moride Y, Brenot F, et al. Appetite suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-16
138. Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin Drug Saf. In press
139. Bays HE, Dujovene CA. Anti-obesity drug development. Expert Opin Invest Drugs 2002; 11: 1189-204
140. Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004; 12: 1197-211
141. Smith BM, Smith JM, Tsai JH, et al. Discovery and SAR of new benzazapines and potent and selective 5-HT2C receptor agonist for the treatment of obesity. Bioorgan Med Chem Lett 2005; 12: 1467-70
142. Smith S, Anderson J, Frank A, et al. The effects of APD356, a selective 5-HT2C agonist, on weight loss in a 4 week study in healthy obese patients [Abstract]. Obes Res 2005; 13 Suppl.: 101-R
143. Halford JCG, Cooper GD, Dovey TM, et al. Pharmacological approaches to obesity treatment; current medical chemistry. CNS Agents 2003; 3: 283-310
144. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-97
145. Woolley ML, Marsden CA, Fone KC. 5-HT6 receptors. Current drug targets: CNS Neurol Disord 2004; 3: 59-79
146. Vickers SP, Dourish CT. Serotonin receptor ligands and the treatment of obesity. Curr Opin Invest Drugs 2004; 5: 377-88
147. Shacham S, Marantz Y, Senderowitz H, et al. Novel 5-HT6 receptor antagonists for the treatment of obesity. Obes Res 2005; 13: A192
148. EPIX Pharmaceuticals. EPIX Pharmaceuticals announces findings from obesity and cognitive impairment studies at Society for Neuroscience Meeting [online]. Available from URL: http://investor.epixpharma.com/phoenix.zhtml?c= 91717&p=irol-newsArticle&ID=917339&highlight [Accessed 2006 Nov 13]
149. Biovitrum's project portfolio within obesity advances [online]. Available from URL: http://www.stockholmbioregion.com/templates/page_517.aspx [Accessed 2006 Nov 13]
150. Halford JCG. Obesity drugs in clinical development. Curr Opin Invest Drugs 2006; 7: 312-8